Predictive value of maspin and Ki-67 expression in transurethral resection specimens in patients with T1 bladder cancer

Tumori

Volumn 98, Issue 3, 2012, Pages 344-350

  Acikalin, Demet ^a   Oner, Ulku ^a   Can, Cavit ^a   Acikalin, Mustafa Fuat ^a   Colak, Ertugrul ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Bladder; Ki 67; Maspin; T1 transitional cell carcinoma

Indexed keywords

KI 67 ANTIGEN; MASPIN;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; TRANSURETHRAL RESECTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; SERPINS; TUMOR MARKERS, BIOLOGICAL; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84867056948     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800311     Document Type: Article

References (39)

1. deVere White RW, Stapp E: Predicting prognosis in patients with superficial bladder cancer. Oncology, 12: 1717-1723, 1998.
2. Stein JP, Penson DF: Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int, 102: 270-275, 2008. (Pubitemid 352019205)
3. Crew JP, O'Brien TS, Harris AL: Bladder cancer angiogenesis, its role in recurrence, stage progression, and as a therapeutic target. Cancer Metastasis Rev, 15: 221-230, 1996. (Pubitemid 26236120)
4. Herr HW: Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol, 80: 762-765, 1997.
5. Marioni G, Staffieri C, Staffieri A, De Filippis C, Blandamura S: Maspin tumour-suppressing activity in head and neck squamous cell carcinoma: emerging evidence and therapeutic perspectives. Acta Otolaryngol, 129: 476-480, 2009.
6. Zhang M, Volpert O, Shi YH, Bouck N: Maspin is an angiogenesis inhibitor. Nat Med, 6: 196-199, 2000. (Pubitemid 30082365)
7. Li Z, Shi HY, Zhang M: Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis. Oncogene, 24: 2008-2019, 2005. (Pubitemid 40516194)
8. Khalkhali-Ellis Z, Hendrix MJ: Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res, 67: 3535-3539, 2007. (Pubitemid 46762133)
9. Cella N, Contreras A, Latha K, Rosen JM, Zhang M: Maspin is physically associated with [beta]1 integrin regulating cell adhesion in mammary epithelial cells. FASEB J, 20: 1510-1512, 2006.
10. Liu J, Yin S, Reddy N, Spencer C, Sheng S: Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res, 64: 1703-1711, 2004. (Pubitemid 38428692)
11. Maass N, Teffner M, Rösel F, Pawaresch R, Jonat W, Nagasaki K, Rudolph P: Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J Pathol, 195: 321-326, 2001.
12. Maass N, Hojo T, Rösel F, Ikeda T, Jonat W, Nagasaki K: Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin Biochem, 34: 303-307, 2001. (Pubitemid 32607573)
13. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, Hartmann J, Knüchel R, Kondo M, Jonas U, Kuczyk M: Expression of the p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer, 95: 337-342, 2001. (Pubitemid 32847047)
14. Yoshizawa K, Nozaki S, Okamune A, Kitahara H, Ohara T, Kato K, Kawashiri S, Yamamoto E: Loss of maspin is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma. J Oral Pathol Med, 38: 535-539, 2009.
15. Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Leo G, Fischetto D, Staffieri A, de Filippis C: Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology, 46: 576-582, 2005. (Pubitemid 40632315)
16. Boltze C, Schneider-Stock R, Meyer F, Peters B, Quednow C, Hoang-Vu C, Roessner A: Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncol Rep, 10: 1783-1787, 2003.
17. Sobin DH, Wittekind Ch: TNM Classification of Malignant Tumours. Wiley-Liss, New York, 2002.
18. Mostofi FK, Sobin LH, Torloni H: Histological typing of urinary bladder tumours. World Health Organization, Geneva, 1973.
19. Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J, Lee KH: Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol, 182: 2625-2631, 2009.
20. Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL: The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol, 157: 800-803, 1997.
21. Soukup V, Babjuk M, Duskova J, Pesl M, Szakáczová M, Zámecník L, Dvorácek J: Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in T1 urothelial urinary bladder carcinoma? Urol Int, 80: 413-418, 2008. (Pubitemid 351915029)
22. Joensuu KM, Leidenius MH, Andersson LC, Heikkilä PS: High expression of maspin is associated with early tumor relapse in breast cancer. Hum Pathol, 40: 1143-1151, 2009.
23. Yu M, Zheng H, Tsuneyama K, Takahashi H, Nomoto K, Xu H, Takano Y: Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression. Hum Pathol, 38: 1248-1255, 2007. (Pubitemid 47058163)
24. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A: Maspin expression is directly associated with biological aggressiveness of thyroid carcinoma. Thyroid, 14: 13-18, 2004. (Pubitemid 38282932)
25. Blandamura S, D'Alessandro E, Giacomelli L, Guzzardo V, Battanello W, Repele M, Ninfo V: Expression of maspin in papillary Ta/T1 bladder neoplasms. Anticancer Res, 28: 471-478, 2008. (Pubitemid 351362855)
26. Beecken W, Engl T, Engels K, Blumenberg C, Oppermann E, Camphausen K, Shing Y, Reinecke G, Jonas D, Blaheta R: Clinical relevance of maspin expression in bladder cancer. World J Urol, 24: 338-344, 2006. (Pubitemid 44138190)
27. Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A, Huland H: Expression of maspin in nonmuscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. Eur Urol, 45: 737-743, 2004. (Pubitemid 38638393)
28. Sugimoto S, Maass N, Takimoto Y, Sato K, Minei S, Zhang M, Hoshikawa Y, Jünemann KP, Jonat W, Nagasaki K: Expression and regulation of tumor suppressor gene maspin in human bladder cancer. Cancer Lett, 203: 209-215, 2004. (Pubitemid 38058688)
29. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, Sheng S: Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer, 51: 31-39, 2006. (Pubitemid 43088622)
30. Mohsin SK, Zhang M, Clark GM, Craig Allred D: Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol, 199: 432-435, 2003. (Pubitemid 36411219)
31. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res, 8: 2924-2932, 2002. (Pubitemid 35025740)
32. Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC, Heighway J: Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions. Oncogene, 22: 8677-8687, 2003. (Pubitemid 38010491)
33. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF: Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst, 101: 114-119, 2009.
34. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y: Ki- 67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res, 12: 7369-7373, 2006. (Pubitemid 46095410)
35. Ye YK, Bi XC, He HC, Han ZD, Dai QS, Liang YX, Zeng GH, Qin WJ, Chen ZN, Zhong WD: CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma. Clin Exp Med, 10: 153-158, 2010.
36. Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C, Muir GH, Tizzani A: Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol, 38: 287-296, 2000. (Pubitemid 30665955)
37. Rodriguez-Alonso A, Pita-Fernandez S, González-CarreróJ, Nogueira-March JL: P53 and Ki-67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol, 41: 182-189, 2002. (Pubitemid 35428886)
38. Krüger S, Mahnken A, Kausch I, Feller AC: P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol, 47: 463-467, 2005. (Pubitemid 40357889)
39. Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F: Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer, 100: 2367-2375, 2004. (Pubitemid 38657884)